Health and Fitness Health and Fitness
Wed, July 25, 2012
[ Wed, Jul 25th 2012 ] - Market Wire
EnteroMedics to Host Second Quarter 2012 Financia .. sults Conference Call and Provide Business Update
[ Wed, Jul 25th 2012 ] - Market Wire
Implant Sciences Wins Contracts to Supply Additio .. s to China for Use by China Police and Bomb Squad
[ Wed, Jul 25th 2012 ] - Market Wire
Acura Pharmaceuticals to Host Second Quarter 2012 .. nancial Results Conference Call on August 8, 2012
[ Wed, Jul 25th 2012 ] - Market Wire
EntreMed Announces Initiation Of Phase 2 Trial In Triple-negative Breast Cancer
[ Wed, Jul 25th 2012 ] - Market Wire
STATS ChipPAC Appoints Gary Tanner as Director
[ Wed, Jul 25th 2012 ] - Market Wire
Sunshine Heart Announces CE Mark for C-Pulse(R) Heart Assist System
Tue, July 24, 2012
[ Tue, Jul 24th 2012 ] - Market Wire
ViroPharma To Release 2012 Second Quarter Financial Results On August 9, 2012
[ Tue, Jul 24th 2012 ] - Market Wire
Almirall und Forest Laboratories geben FDA-Zulass .. r langfristige Erhaltungstherapie von COPD-Patien
[ Tue, Jul 24th 2012 ] - Market Wire
Almirall et Forest Laboratories annoncent l'appro .. a" Pressaira" pour le traitement d'entretien long
[ Tue, Jul 24th 2012 ] - Market Wire
Alexza to Announce 2012 Second Quarter Financial Results on Wednesday, August 8, 2012
[ Tue, Jul 24th 2012 ] - Market Wire
Anthera Pharmaceuticals Announces Exercise in Ful .. and Completion of Public Offering of Common Stock
[ Tue, Jul 24th 2012 ] - Market Wire
Cytokinetics to Announce Second Quarter Results on July 31, 2012
[ Tue, Jul 24th 2012 ] - Market Wire
TPI Provides Progress Update on Qionglai Facility (QLF) Construction
[ Tue, Jul 24th 2012 ] - Market Wire
ABC News Affiliate Airs Segment Describing Implan .. "Company on the Front Lines of Airport Security"
[ Tue, Jul 24th 2012 ] - Market Wire
Winner Medical Enters into Definitive Merger Agreement with Winner Holding Limited
[ Tue, Jul 24th 2012 ] - Market Wire
Rosetta Genomics and Precision Therapeutics Enter .. Co-Marketing Agreement for miRview mets(2) Assay
[ Tue, Jul 24th 2012 ] - Market Wire
BIOLASE Announces Opening of Corporate Technology and Training Center
[ Tue, Jul 24th 2012 ] - Market Wire
Neogen reports year end results
[ Tue, Jul 24th 2012 ] - Market Wire
Aeterna Zentaris Requests Fast Track Designation .. Diagnostic Test for Adult Growth Hormone Deficien
[ Tue, Jul 24th 2012 ] - Market Wire
Nephros Announces Expansion of U.S. Sales Team
[ Tue, Jul 24th 2012 ] - Market Wire
Reliv International Names Ryan Montgomery President
[ Tue, Jul 24th 2012 ] - Market Wire
Sarepta Therapeutics Announces Significant Clinic .. ter 36 Weeks in Phase IIb Study for the Treatment
[ Tue, Jul 24th 2012 ] - Market Wire
Enzalutamide Granted Priority Review by U.S. FDA .. f Castration-Resistant Prostate Cancer in Patient
[ Tue, Jul 24th 2012 ] - Market Wire
Auxilium Pharmaceuticals to Announce Second Quart .. Conduct Conference Call on Tuesday, July 31, 2012
Mon, July 23, 2012
[ Mon, Jul 23rd 2012 ] - Market Wire
Galapagos Delivers Candidate Drug in Osteoarthritis Alliance With Servier
[ Mon, Jul 23rd 2012 ] - Market Wire
BD Board of Directors Elects Rebecca W. Rimel
[ Mon, Jul 23rd 2012 ] - Market Wire
David Cutler to Resign as President and CEO, Continue as Director
[ Mon, Jul 23rd 2012 ] - Market Wire
Sanofi US Launches Collaborate Activate Innovation Challenge
[ Mon, Jul 23rd 2012 ] - Market Wire
Amgen Announces Webcast of 2012 Second Quarter Financial Results
[ Mon, Jul 23rd 2012 ] - Market Wire
Sarepta Announces Conference Call and Webcast on .. scuss 36-Week 6-Minute Walk Test Results From the

Sarepta Announces Conference Call and Webcast on Tuesday, July 24, 2012, to Discuss 36-Week 6-Minute Walk Test Results From the


Published on 2012-07-23 13:27:01 - Market Wire
  Print publication without navigation


July 23, 2012 16:10 ET

Sarepta Announces Conference Call and Webcast on Tuesday, July 24, 2012, to Discuss 36-Week 6-Minute Walk Test Results From the Phase IIb DMD Study

CAMBRIDGE, MA--(Marketwire - Jul 23, 2012) - Sarepta Therapeutics, Inc. (NASDAQ: [ SRPT ]), a developer of RNA-based therapeutics, today announced it will hold a conference call at 8:00 a.m. EDT (5:00 a.m. PDT) on Tuesday, July 24, 2012 to discuss 36-week 6-minute walk test results from its Phase IIb study evaluating eteplirsen for the treatment of Duchenne muscular dystrophy (DMD).

The conference call may be accessed by dialing 866.783.2139 for domestic callers and 857.350.1598 for international callers. The passcode for the call is 77518015. Please specify to the operator that you would like to join the "Sarepta Therapeutics 36-Week Clinical Results Call." The conference call will be webcast live under the events section of Sarepta's website at [ www.sareptatherapeutics.com ] and will be archived there following the call for 90 days. Please connect to Sarepta's website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary.

About Sarepta Therapeutics

Sarepta Therapeutics -- formerly AVI BioPharma -- is focused on developing first-in-class RNA-based therapeutics to improve and save the lives of people affected by serious and life-threatening rare and infectious diseases. The Company's diverse pipeline includes its lead program eteplirsen, for Duchenne muscular dystrophy, as well as potential treatments for some of the world's most lethal infectious diseases. Sarepta aims to build a leading, independent biotech company dedicated to translating its RNA-based science into transformational therapeutics for patients who face significant unmet medical needs. For more information, please visit us at [ www.sareptatherapeutics.com ].


Contributing Sources